SCHEMBL3324410

SCHEMBL3324410

CCC1CCCCN1CCCN

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.47
S1PR1 P21453 3/20 0.42
S1PR3 Q99500 3/20 0.42
S1PR5 Q9H228 3/20 0.42
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
CHRM2 P08172 1/20 0.40
CHRM1 P11229 1/20 0.40
MAPK1 P28482 1/20 0.39
TERT O14746 2/20 0.39
S1PR4 O95977 1/20 0.38
TSHR P16473 1/20 0.38
ALDH1A1 P00352 1/20 0.38
CRHBP P24387 1/20 0.38
CRHR2 Q13324 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
MAPT P10636 2/20 0.37
LMNA P02545 1/20 0.36
GAA P10253 1/20 0.36
PKM P14618 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21777969 1.00 HSD17B10 (0.47) HSD17B10S1PR1S1PR3S1PR5KMT2A
SCHEMBL5009345 0.89 MAPK1 (0.41) HSD17B10S1PR1S1PR3S1PR5KMT2A
SCHEMBL10220860 0.85 S1PR1 (0.51) HSD17B10S1PR1S1PR3S1PR5CHRM2
SCHEMBL7647760 0.83 S1PR1 (0.47) HSD17B10S1PR1S1PR3S1PR5CHRM2
SCHEMBL12011344 0.82 HRH3 (0.37) HSD17B10S1PR1S1PR3S1PR5KMT2A
SCHEMBL12011342 0.82 HRH3 (0.37) HSD17B10S1PR1S1PR3S1PR5KMT2A
SCHEMBL23828673 0.82 S1PR1 (0.46) HSD17B10S1PR1S1PR3S1PR5KMT2A
SCHEMBL23828675 0.82 S1PR1 (0.50) HSD17B10S1PR1S1PR3S1PR5KMT2A
SCHEMBL9824391 0.82 S1PR1 (0.38) HSD17B10S1PR1S1PR3S1PR5CHRM2
SCHEMBL2118732 0.81 HSD17B10 (0.47) HSD17B10S1PR1S1PR3S1PR5KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748422-B2 Pharmaceutical compositions containing quinazoline derivatives for treating as serotonin receptor antagonist KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2014-06-10 US claimed
US-20090054433-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING QUINAZOLINE DERIVATIVES FOR TREATING AS SEROTONIN RECEPTOR ANTAGONIST KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2009-02-26 US claimed
US-12145912-B2 Ionizable lipidoids and their uses MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2024-11-19 US disclosed
US-20230322689-A1 IONIZABLE LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS SunVax mRNA Therapeutics Inc. (US) 2023-10-12 US disclosed
US-20230322689-A1 IONIZABLE LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS SunVax mRNA Therapeutics Inc. (US) 2023-10-12 US disclosed
WO-2023196527-A2 IONIZABLE LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS SunVax mRNA Therapeutics Inc. (US) 2023-10-12 WO disclosed
US-20230257353-A1 IONIZABLE LIPIDOIDS AND THEIR USES MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2023-08-17 US disclosed
US-20230257353-A1 IONIZABLE LIPIDOIDS AND THEIR USES MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2023-08-17 US disclosed
US-11459304-B2 Ionizable lipidoids and their uses MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2022-10-04 US disclosed
US-20200109121-A1 IONIZABLE LIPIDOIDS AND THEIR USES MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2020-04-09 US disclosed
EP-2139472-B1 TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2016-01-13 EP disclosed
US-20100022509-A1 Inhibitors of MshC and Homologs Thereof, and Methods of Identifying Same NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2010-01-28 US disclosed
US-20090054433-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING QUINAZOLINE DERIVATIVES FOR TREATING AS SEROTONIN RECEPTOR ANTAGONIST KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2009-02-26 US disclosed
EP-2000176-A1 Tetrahydroindole derivatives as NADPH Oxidase inhibitors GenKyo Tex (CH) 2008-12-10 EP disclosed
WO-2008036139-A2 INHIBITORS OF MSHC AND HOMOLOGS THEREOF, AND METHODS OF IDENTIFYING SAME THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2008-03-27 WO disclosed
WO-2008007835-A1 2,4-QUINAZOLINE DERIVATIVES HAVING ACTIVITY TO T-TYPE CALCIUM CHANNEL AND PREPARATION METHOD THEREOF KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2008-01-17 WO disclosed
WO-2008007835-A1 2,4-QUINAZOLINE DERIVATIVES HAVING ACTIVITY TO T-TYPE CALCIUM CHANNEL AND PREPARATION METHOD THEREOF KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2008-01-17 WO disclosed
WO-2007117180-A1 AZAHETEROCYCLES, COMBINATORY LIBRARY, FOCUSED LIBRARY, PHARMACEUTICAL COMPOSITION AND METHODS FOR THE PRODUCTION THEREOF 'CHEMICAL DIVERSITY RESEARCH INSTITUTE' LTD. (RU) 2007-10-18 WO disclosed
US-4992150-A Telomer with alpha-olefin;oil and fuel additive NIPPON OIL CO, LTD. (JP) 1991-02-12 US disclosed
EP-0068806-A2 Basic acyl amides of (5-amino-1,3-dialkylpyrazol-4-yl)(aryl)methanones, processes for their production, and pharmaceutical compositions containing such compounds WARNER-LAMBERT COMPANY (US) 1983-01-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257353-A1 IONIZABLE LIPIDOIDS AND THEIR USES TTR, PYGL, FABP1 HSD17B10 1257/4885S1PR1 600/4885S1PR3 871/4885
US-20100022509-A1 Inhibitors of MshC and Homologs Thereof, and Methods of Identifying Same ICMT, TST, OGA HSD17B10 639/4885S1PR1 3974/4885S1PR3 3986/4885
US-12145912-B2 Ionizable lipidoids and their uses TTR, PYGL, FABP1 HSD17B10 1257/4885S1PR1 600/4885S1PR3 871/4885
US-11459304-B2 Ionizable lipidoids and their uses TTR, PYGL, FABP1 HSD17B10 1257/4885S1PR1 600/4885S1PR3 871/4885
US-20200109121-A1 IONIZABLE LIPIDOIDS AND THEIR USES TTR, PYGL, FABP1 HSD17B10 1257/4885S1PR1 600/4885S1PR3 871/4885
US-20090054433-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING QUINAZOLINE DERIVATIVES FOR TREATING AS SEROTONIN RECEPTOR ANTAGONIST HTR3A, HTR3B, HTR3E HSD17B10 2985/4885S1PR1 1073/4885S1PR3 496/4885
US-20230322689-A1 IONIZABLE LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS PHOSPHO1, SGMS1, PLIN3 HSD17B10 3002/4885S1PR1 931/4885S1PR3 726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.